GlassScriptPhysician profile
Alyssa M Yee
NPI 1598158842
$11,540.13
in general payments reported to CMS, 2019-2025
24 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $39.30 · 2021: $624 · 2022: $6,352 · 2023: $1,901 · 2024: $1,479 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,525.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $4,295.11 | 2021-2025 | Titan, Coloplast Tfl Drive |
| Boston Scientific Corporation | $2,987.38 | 2020-2025 | Rezum Generator |
| Teleflex LLC | $1,489.09 | 2022-2025 | Urolift, Barrigel |
| Endo Pharmaceuticals INC. | $1,005.16 | 2021-2024 | Xiaflex |
| Endo USA, INC. | $306.86 | 2024 | Xiaflex |
| Tolmar, INC. | $285.40 | 2023-2025 | Jatenzo, Eligard |
| Clarus Therapeutics INC. | $195.60 | 2021 | |
| Sumitomo Pharma America, INC. | $182.33 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $152.51 | 2023-2024 | Veozah |
| Myovant Sciences INC. | $134.78 | 2022 | |
| Progenics Pharmaceuticals, INC. | $124.58 | 2022 | |
| Medtronic, INC. | $85.45 | 2025 | Interstim |
| Urogen Pharma, INC. | $53.68 | 2025 | |
| Abbvie INC. | $48.99 | 2025 | |
| Pfizer INC. | $34.87 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $28.54 | 2023 | Gentlecath Glide |
| Janssen Biotech, INC. | $22.45 | 2023 | Erleada |
| Mycovia Pharmaceuticals, INC. | $17.78 | 2022 | |
| Ascend Therapeutics US, LLC | $16.59 | 2023 | |
| Millicent US INC | $16.49 | 2022 | |
| Urovant Sciences INC | $15.37 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.05 | 2025 | Wainua |
| Acerus Pharmaceuticals Corporation | $14.29 | 2022 | |
| Innovation Technologies INC | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.